View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 23, 2022

Ribon initiates Phase I trial of atopic dermatitis treatment

The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.

Ribon Therapeutics has commenced the healthy volunteer segment of its first-in-human Phase I clinical trial to analyse the potential of its oral therapy, RBN-3143, to treat atopic dermatitis.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

A poly (ADP-ribose) polymerase family member 14 (PARP14) inhibitor, RBN-3143 could be used to treat various inflammatory diseases.

Expressed in tissues of inflammatory diseases, PARP14 facilitates the inflammatory cells infiltration such as eosinophils and neutrophils, the decline of which could have advantages over existing treatments.

Selectively hindering PARP14 causes a decline in alarmins and IL-17 and IL-4/13 signalling pathway dampening. 

The single ascending dose and multiple ascending dose trial will analyse the safety and pharmacokinetics of RBN-3143.

Ribon Therapeutics president and CEO Prakash Raman said: “The news of the initiation of RBN-3143, our second programme to move into the clinic, is an important advancement for Ribon that broadens our Company’s portfolio to now include first-in-class programmes in both oncology and inflammatory diseases, leveraging our pioneering research in the role of NAD+-utilising enzymes in stress support pathways. 

“As a first-in-class, oral small molecule inhibitor of PARP14, RBN-3143 has the potential to be a differentiated therapy for the treatment of numerous inflammatory diseases.”

Apart from RBN-3143, the portfolio of the company comprises another first-in-class clinical programme, RBN-2397, targeting various indications in oncology and inflammatory diseases.

In July last year, Ribon raised $65m in a funding round led by Deerfield Management and US Venture Partners.

New investors Avego Bioscience Capital , GV, Monashee Investment Management and Peregrine Ventures also took part in the financing round.

The funds were used to advance the clinical development of its precision treatment candidates.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena